EUCTR2013-001384-23-SK进行中（未招募）不适用
A RANDOMIZED, OPEN-LABEL, MULTI-CENTER, ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF THE REG1 ANTICOAGULATION SYSTEM COMPARED TO BIVALIRUDIN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTIO
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 13,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. The study population will consist of patients with CAD undergoing PCI. Three key subgroups will be included as follows:
- •a. Subgroup A: Patients with ischemic symptoms at rest and positive cardiac biomarkers (troponin I or T or creatine kinase-MB) related to an acute coronary syndrome event within 7 days;
- •b. Subgroup B: Patients not meeting criteria for Subgroup A with at least one of the following risk factors:
- •Current presentation with an acute coronary syndrome
- •with positive cardiac biomarkers > 7 days prior to randomization
- •Current presentation with unstable angina (ACS without positive
- •cardiac biomarkers)
- •Age >70 years
- •Chronic kidney disease (estimated CrCl < 60 mL/min)
- •Planned multivessel PCI
- •Prior CABG surgery
- •Peripheral vascular disease;
- •c. Subgroup C: Patients with negative cardiac biomarkers and no risk
- •factor, thereby not meeting criteria for Subgroup A or B;
- •2. Willing and able to sign an Institutional Review Board/Ethics
- •Committee (IRB/EC) approved informed consent prior to any studyrelated
- •activities;
- •3. Male or female age 18 or greater;
- •4. If female of childbearing potential, must have a negative urine or
- •serum pregnancy test or be post-menopausal for at least 1 year prior to
- •randomization. Females of childbearing potential and males with
- •partners of childbearing potential must
- •be using effective contraception to be eligible. Women who are nursing
- •or lactating should not nurse while in the study as
- •the effects of this drug on nursing has not been studied. It is the
- •Investigator's responsibility for determining whether the patient is
- •using effective contraception and refraining from nursing for study
- •participation;
- •5. Subject is able and willing to comply with the protocol and all study
- •procedures,
- •including but not limited to the 20 + 4 hour blood draw, Endpoint (Day 3
- •+7), End-of-Study (Day 30), and 6-month vital status assessments.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 6600
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 6600
排除标准
- •1. Acute ST-segment elevation myocardial infarction within 48 hours of randomization; of the following:
- •2. Evidence of current clinical instability including the following:
- •a. Sustained systolic blood pressure <90 mm Hg or cardiogenic shock;
- •b. Suspected acute myocarditis, pericarditis, endocarditis, or cardiac tamponade;
- •c. Suspected dissecting aortic aneurysm;
- •3. Evidence of a contraindication to anticoagulation or increased risk of bleeding such as:
- •a. Any evidence or history of intracranial bleeding or intracranial aneurysm;
- •b. Known hypercoagulable state, including treatment for malignancy (excluding basal cell skin carcinoma) in the past year, or coagulopathy with abnormal bleeding tendency;
- •c. History of intraocular hemorrhage other than due to diabetic retinopathy;
- •d. History of thrombocytopenia associated with abnormal bleeding;
- •e. History of thrombocytosis associated with a thrombotic event;
- •f. Severe trauma, fracture, major surgery, or biopsy of a parenchymal organ within 3 months;
- •g. Prolonged cardiopulmonary resuscitation within 3 months;
- •h. Major gastrointestinal bleeding within 3 months;
- •i. Spontaneous genitourinary bleeding within 3 months;
- •j. Any planned additional invasive procedure within 30 days after randomization;
- •4. Use of any investigational drug or device within 30 days of randomization or the planned use of an investigational drug or device through EOS (Day 30 follow-up);
- •5. Use of the following antithrombotic agents:
- •a. Fibrinolytic agents within 48 hours;
- •b. GP IIb/IIIa inhibitors within 24 hours;
- •c. Bivalirudin within 24 hours
- •d. Prior exposure to any component of REG1;
- •6. Baseline hemoglobin (Hgb) <9 g/dL or equivalent;
- •7. Renal impairment as determined by any one of the following:
- •a. Baseline estimated glomerular filtration rate (GFR) = 10 mL/min/1.73m²;
- •b. Currently undergoing renal replacement therapy (hemodialysis or peritoneal dialysis);
- •c. Degree of renal impairment for which use of bivalirudin is prohibited or contraindicated per local label instructions;
- •8. Baseline platelet count <100,000/mm3
- •9. Known allergy or intolerance to aspirin, to all available ADP/P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor), or to bivalirudin or REG1 (or any of their respective components); ;
- •10. The following planned procedures:
- •a. Planned staged PCI procedure within 30 days after randomization;
- •b. Planned CABG or valve surgery within 30 days after randomization;
- •11. Any other medical or psychiatric condition that in the Investigator’s judgment precludes participation in the study.
研究者
相似试验
进行中（未招募）
不适用
A study to evaluate the efficacy and safety of a new anticoagulation drugREG1 compared with bivalirudin in patients undergoing angioplasty.EUCTR2013-001384-23-PTRegado Biosciences, Inc.13,200
进行中（未招募）
不适用
A study to evaluate the efficacy and safety of a new anticoagulation drugREG1 compared with bivalirudin in patients undergoing angioplasty.Coronary Artery Disease (CAD) in patients undergoing Percutaneous Coronary Intervention (PCI)MedDRA version: 16.1Level: HLTClassification code 10011085Term: Ischaemic coronary artery disordersSystem Organ Class: 100000004849EUCTR2013-001384-23-DKRegado Biosciences, Inc.13,200
进行中（未招募）
不适用
A study to evaluate the efficacy and safety of a new anticoagulation drugREG1 compared with bivalirudin in patients undergoing angioplasty.EUCTR2013-001384-23-DERegado Biosciences, Inc.13,200
进行中（未招募）
不适用
A study to evaluate the efficacy and safety of a new anticoagulation drugREG1 compared with bivalirudin in patients undergoing angioplasty.Coronary Artery Disease (CAD) in patients undergoing Percutaneous Coronary Intervention (PCI)MedDRA version: 14.1Level: HLTClassification code 10011085Term: Ischaemic coronary artery disordersSystem Organ Class: 100000004849EUCTR2013-001384-23-ESRegado Biosciences, Inc.13,200
进行中（未招募）
不适用
A study to evaluate the efficacy and safety of a new anticoagulation drugREG1 compared with bivalirudin in patients undergoing angioplasty.Coronary Artery Disease (CAD) in patients undergoing Percutaneous Coronary Intervention (PCI)MedDRA version: 14.1Level: HLTClassification code 10011085Term: Ischaemic coronary artery disordersSystem Organ Class: 100000004849EUCTR2013-001384-23-ITRegado Biosciences, Inc.13,200